280 research outputs found

    Image Processing: towards a System on Chip

    Get PDF

    Extraction de trajectoires basée sur la cinématique dans les séquences d'images

    Get PDF
    - Le suivi de personnes en mouvements sans aucune connaissance à priori du nombre de personnes présentes dans la scène et en prenant en compte les différents problèmes d'occlusions, s'avère difficile. Une détection de mouvement nous permet d'avoir des régions avec un nombre important de sous-segmentations et de sur-segmentations dues aux mauvaises conditions d'acquisition. L'étape de suivi qui doit prendre en compte tous ces problèmes, est réalisée avec l'algorithme EM (Expectation Maximization). Ce dernier utilise un model cinématique : on suppose que le mouvement apparent est rectiligne et uniforme, cette hypothèse reste localement valide pour beaucoup d'applications. Grâce à cette approche, des résultats satisfaisants ont été obtenus sur plusieurs séquences et ce sans aucune initialisation préalable

    A 2022 τ\tau-Herculid meteor cluster from an airborne experiment: automated detection, characterization, and consequences for meteoroids

    Full text link
    Context. The existence of meteor clusters has long since been a subject of speculation and so far only seven events have been reported, among which two involve less than five meteors, and three were seen during the Leonid storms. Aims. The 1995 outburst of Comet 73P/Schwassmann-Wachmann was predicted to result in a meteor shower in May 2022. We detected the shower, proved this to be the result of this outburst, and detected another meteor cluster during the same observation mission. Methods. The {\tau}-Herculids meteor shower outburst on 31 May 2022 was continuously monitored for 4 hours during an airborne campaign. The video data were analyzed using a recently developed computer-vision processing chain for meteor real-time detection. Results. We report and characterize the detection of a meteor cluster involving 38 fragments, detected at 06:48 UT for a total duration of 11.3 s. The derived cumulative size frequency distribution index is relatively shallow: s = 3.1. Our open-source computer-vision processing chain (named FMDT) detects 100% of the meteors that a human eye is able to detect in the video. Classical automated motion detection assuming a static camera was not suitable for the stabilized camera setup because of residual motion. Conclusions. From all reported meteor clusters, we crudely estimate their occurrence to be less than one per million observed meteors. Low heliocentric distance enhances the probability of such meteoroid self-disruption in the interplanetary space.Comment: 6 pqges, 5 figure

    Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO)

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Chronic recurrent multifocal osteomyelitis (CRMO) is an inflammatory, non-infectious osteopathy that affects predominantly patients ≤ 18 years of age. There is no uniformly effective treatment. Our objective is to describe clinical, magnetic resonance imaging (MRI), and bone resorption response to intravenous pamidronate in pediatric CRMO.</p> <p>Methods</p> <p>We report our prospectively documented experience with all CRMO patients treated with pamidronate between 2003 and 2008 at a tertiary pediatric centre. Pamidronate was administered as intravenous cycles. The dose of pamidronate varied among subjects but was given as monthly to every 3 monthly cycles depending on the distance the patient lived from the infusion center. Maximum cumulative dose was ≤ 11.5 mg/kg/year. Pamidronate treatment was continued until resolution of MRI documented bone inflammation. Visual analog scale for pain (VAS) and bone resorption marker urine N-telopeptide/urine creatinine (uNTX/uCr) were measured at baseline, preceding each subsequent pamidronate treatment, at final follow-up, and/or at time of MRI confirmed CRMO flare. MRI of the affected site(s) was obtained at baseline, preceding every 2<sup>nd </sup>treatment, and with suspected CRMO recurrence.</p> <p>Results</p> <p>Nine patients (5 F: 4 M) were treated, with a median (range) age at treatment of 12.9 (4.5–16.3) years, and median (range) duration of symptoms of 18 (6–36) months. VAS decreased from 10/10 to 0–3/10 by the end of first 3–day treatment for all patients. The mean (range) time to complete MRI resolution of bone inflammation was 6.0 (2–12) months. The mean (confidence interval (CI)) baseline uNTX/uCr was 738.83 (CI 464.25, 1013.42)nmol/mmol/creatinine and the mean (CI) decrease from baseline to pamidronate discontinuation was 522.17 (CI 299.77, 744.56)nmol/mmol/creatinine. Median (range) of follow-up was 31.4 (24–54) months. Four patients had MRI confirmed CRMO recurrence, which responded to one pamidronate re-treatment. The mean (range) uNTX/uCr change as a monthly rate from the time of pamidronate discontinuation to flare was 9.41 (1.38–19.85)nmol/mmol/creatinine compared to -29.88 (-96.83–2.01)nmol/mmol/creatinine for patients who did not flare by the time of final follow-up.</p> <p>Conclusion</p> <p>Pamidronate resulted in resolution of pain and MRI documented inflammation in all patients. No patient flared while his/her uNTX/uCr remained suppressed. We propose that pamidronate is an effective second-line therapy in persistent CRMO.</p

    Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design:An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO

    Get PDF
    Introduction Chronic nonbacterial osteomyelitis (CNO) is a rare autoinflammatory bone disorder primarily affecting children and adolescents. It can lead to chronic pain, bony deformities and fractures. The pathophysiology of CNO is incompletely understood. Scientific evidence suggests dysregu-lated expression of pro- and anti-inflammatory cytokines to be centrally involved. Currently, treatment is largely based on retrospective observational studies and expert opinion. Treatment usually includes nonsteroidal anti-inflammatory drugs and/or glucocorticoids, followed by a range of drugs in unresponsive cases. While randomised clinical trials are lacking, retrospective and prospective non-controlled studies suggest effectiveness of TNF inhibitors and bisphosphonates. The objective of the Bayesian consensus meeting was to quantify prior expert opinion. Methods Twelve international CNO experts were randomly chosen to be invited to a Bayesian prior elicitation meeting. Results Results showed that a typical new patient treated with pamidronate would have an 84% chance of improvement in their pain score relative to baseline at 26 weeks and an 83% chance on adalimumab. Experts thought there was a 50% chance that a new typical patient would record a pain score of 28mm (pamidronate) to 30mm (adalimumab) or better at 26 weeks. There was a modest trend in prior opinion to indicate an advantage of pamidronate vs adalimumab, with a 68% prior chance that pamidronate is superior to adalimumab by some margin. However, it is clear that there is considerable uncertainty about the precise relative merits of the two treatments. Conclusions The rarity of CNO leads to challenges in conducting randomised controlled trials with sufficient power to provide a definitive outcome. We address this using a Bayesian design, and here describe the process and outcome of the elicitation exercise to establish expert prior opinion. This opinion will be tested in the planned prospective CNO study. The process for establishing expert consensus opinion in CNO will be helpful for developing studies in other rare paediatric diseases

    100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report

    Get PDF
    BACKGROUND: The U.K. 100,000 Genomes Project is in the process of investigating the role of genome sequencing in patients with undiagnosed rare diseases after usual care and the alignment of this research with health care implementation in the U.K. National Health Service. Other parts of this project focus on patients with cancer and infection. METHODS: We conducted a pilot study involving 4660 participants from 2183 families, among whom 161 disorders covering a broad spectrum of rare diseases were present. We collected data on clinical features with the use of Human Phenotype Ontology terms, undertook genome sequencing, applied automated variant prioritization on the basis of applied virtual gene panels and phenotypes, and identified novel pathogenic variants through research analysis. RESULTS: Diagnostic yields varied among family structures and were highest in family trios (both parents and a proband) and families with larger pedigrees. Diagnostic yields were much higher for disorders likely to have a monogenic cause (35%) than for disorders likely to have a complex cause (11%). Diagnostic yields for intellectual disability, hearing disorders, and vision disorders ranged from 40 to 55%. We made genetic diagnoses in 25% of the probands. A total of 14% of the diagnoses were made by means of the combination of research and automated approaches, which was critical for cases in which we found etiologic noncoding, structural, and mitochondrial genome variants and coding variants poorly covered by exome sequencing. Cohortwide burden testing across 57,000 genomes enabled the discovery of three new disease genes and 19 new associations. Of the genetic diagnoses that we made, 25% had immediate ramifications for clinical decision making for the patients or their relatives. CONCLUSIONS: Our pilot study of genome sequencing in a national health care system showed an increase in diagnostic yield across a range of rare diseases. (Funded by the National Institute for Health Research and others.)
    corecore